Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Malignant Melanoma

  Free Subscription


Articles published in Cancer Lett

Retrieve available abstracts of 42 articles:
HTML format



Single Articles


    August 2024
  1. GAO Q, Li N, Pan Y, Chu P, et al
    Hepatocyte growth factor promotes melanoma metastasis through ubiquitin-specific peptidase 22-mediated integrins upregulation.
    Cancer Lett. 2024 Aug 31:217196. doi: 10.1016/j.canlet.2024.217196.
    PubMed     Abstract available


  2. FLETCHER K, Cortellini A, Ganta T, Kankaria R, et al
    Safety and efficacy outcomes of early cessation of anti-PD1 therapy in patients 80 years or older: A retrospective cohort study.
    Cancer Lett. 2024;596:217001.
    PubMed     Abstract available


  3. KIM YJ, Lee M, Kim EH, Lee S, et al
    Real-world incidences and risk factors of immune-related adverse events in patients treated with immune checkpoint inhibitors: A nationwide retrospective cohort study.
    Cancer Lett. 2024;596:216998.
    PubMed     Abstract available


    July 2024
  4. LIU M, Zhao Z, Wang C, Sang S, et al
    Harnessing genetic interactions for prediction of immune checkpoint inhibitors response signature in cancer cells.
    Cancer Lett. 2024;594:216991.
    PubMed     Abstract available


  5. FU Z, Zhang L, Chen R, Zhan J, et al
    Biphasic co-detection of melanoma aneuploid tumor cells and tumor endothelial cells in guidance of specifying the field cancerized surgical excision margin and administering immunotherapy.
    Cancer Lett. 2024;598:217099.
    PubMed     Abstract available


    June 2024
  6. ZHANG X, Cui X, Li P, Zhao Y, et al
    EGC enhances tumor antigen presentation and CD8(+) T cell-mediated antitumor immunity via targeting oncoprotein SND1.
    Cancer Lett. 2024;592:216934.
    PubMed     Abstract available


  7. LIAO Q, Shi H, Yang J, Ge S, et al
    FTO elicits tumor neovascularization in cancer-associated fibroblasts through eliminating m(6)A modifications of multiple pro-angiogenic factors.
    Cancer Lett. 2024;592:216911.
    PubMed     Abstract available


    May 2024
  8. WANG J, Hirose H, Du G, Chong K, et al
    Corrigendum to "P-REX1 amplification promotes progression of cutaneous melanomavia the PAK1/P38/MMP-2 pathway" [Cancer Lett. 407 (2017) 66-75].
    Cancer Lett. 2024 May 23:216966. doi: 10.1016/j.canlet.2024.216966.
    PubMed    


    April 2024
  9. JIA Y, Zhang F, Meng X, Andreev D, et al
    Osteocytes support bone metastasis of melanoma cells by CXCL5.
    Cancer Lett. 2024 Apr 6:216866. doi: 10.1016/j.canlet.2024.216866.
    PubMed     Abstract available


  10. WANG L, Liu X, Han Y, Tsai HI, et al
    TRAF6 enhances PD-L1 expression through YAP1-TFCP2 signaling in melanoma.
    Cancer Lett. 2024 Apr 5:216861. doi: 10.1016/j.canlet.2024.216861.
    PubMed     Abstract available


    February 2024
  11. MIRZAEI H, Salehi H, Oskuee RK, Mohammadpour A, et al
    Retraction notice to "The therapeutic potential of human adipose-derived mesenchymal stem cells producing CXCL10 in a mouse melanoma lung metastasis model" [Cancer Lett. 419 (2018) 30-39].
    Cancer Lett. 2024 Feb 2:216670. doi: 10.1016/j.canlet.2024.216670.
    PubMed     Abstract available


    January 2024
  12. ZHANG J, Joshua AM, Yue L, O'Meara CH, et al
    Targeted therapy, immunotherapy, and small molecules and peptidomimetics as emerging immunoregulatory agents for melanoma.
    Cancer Lett. 2024 Jan 26:216633. doi: 10.1016/j.canlet.2024.216633.
    PubMed     Abstract available


  13. LIU C, Cheng X, Han K, Hong L, et al
    A novel molecular subtyping based on multi-omics analysis for prognosis predicting in colorectal melanoma: A 16-year prospective multicentric study.
    Cancer Lett. 2024 Jan 19:216663. doi: 10.1016/j.canlet.2024.216663.
    PubMed     Abstract available


    November 2023
  14. CERDIDO S, Abrisqueta M, Sanchez-Beltran J, Lambertos A, et al
    MGRN1 depletion promotes intercellular adhesion in melanoma by upregulation of E-cadherin and inhibition of CDC42.
    Cancer Lett. 2023;581:216484.
    PubMed     Abstract available


  15. HU X, Hu Z, Zhang H, Zhang N, et al
    Deciphering the tumor-suppressive role of PSMB9 in melanoma through multi-omics and single-cell transcriptome analyses.
    Cancer Lett. 2023 Nov 7:216466. doi: 10.1016/j.canlet.2023.216466.
    PubMed     Abstract available


    September 2023
  16. XU M, Li S
    Nano-drug delivery system targeting tumor microenvironment: A prospective strategy for melanoma treatment.
    Cancer Lett. 2023 Sep 18:216397. doi: 10.1016/j.canlet.2023.216397.
    PubMed     Abstract available


    July 2023
  17. ZHANG X, Hu Z, Wang X, Li L, et al
    Corrigendum to "ANXA10 promotes melanoma metastasis by suppressing E3 ligase TRIM41-directed PKD1 degradation" [Cancer Lett. 519 (2021) 237-249].
    Cancer Lett. 2023 Jul 18:216310. doi: 10.1016/j.canlet.2023.216310.
    PubMed    


    April 2023
  18. ZHAN D, Zheng N, Zhao B, Cheng F, et al
    Expanding individualized therapeutic options via genoproteomics.
    Cancer Lett. 2023;560:216123.
    PubMed     Abstract available


    March 2023
  19. ZHAO J, Gao N, Xu J, Zhu X, et al
    Novel strategies in melanoma treatment using silver nanoparticles.
    Cancer Lett. 2023 Mar 27:216148. doi: 10.1016/j.canlet.2023.216148.
    PubMed     Abstract available


    December 2022
  20. DENG S, Banerjee S, Chen H, Pochampally S, et al
    SB226, an inhibitor of tubulin polymerization, inhibits paclitaxel-resistant melanoma growth and spontaneous metastasis.
    Cancer Lett. 2022 Dec 31:216046. doi: 10.1016/j.canlet.2022.216046.
    PubMed     Abstract available


    October 2022
  21. PALAZZO A, Hernandez-Vargas H, Goehrig D, Medard JJ, et al
    Transformed cells after senescence give rise to more severe tumor phenotypes than transformed non-senescent cells.
    Cancer Lett. 2022;546:215850.
    PubMed     Abstract available


    August 2022
  22. LIU Y, Wang X, Zhu W, Sui Z, et al
    TRPML1-induced autophagy inhibition triggers mitochondrial mediated apoptosis.
    Cancer Lett. 2022;541:215752.
    PubMed     Abstract available


    July 2022
  23. DU Z, Feng Y, Zhang H, Liu J, et al
    Melanoma-derived small extracellular vesicles remodel the systemic onco-immunity via disrupting hematopoietic stem cell proliferation and differentiation.
    Cancer Lett. 2022 Jul 31:215841. doi: 10.1016/j.canlet.2022.215841.
    PubMed     Abstract available


  24. TYAGI A, Wu SY, Watabe K
    Metabolism in the progression and metastasis of brain tumors.
    Cancer Lett. 2022;539:215713.
    PubMed     Abstract available


    May 2022
  25. LAURIN KM, Coutu-Beaudry K, Salazar A, Meribout N, et al
    Low expression of PGC-1beta and other mitochondrial biogenesis modulators in melanoma is associated with growth arrest and the induction of an immunosuppressive gene expression program dependent on MEK and IRF-1.
    Cancer Lett. 2022 May 17:215738. doi: 10.1016/j.canlet.2022.215738.
    PubMed     Abstract available


    October 2021
  26. TIAN C, Liu J, Zhou H, Li J, et al
    Enhanced anti-tumor response elicited by a novel oncolytic HSV-1 engineered with an anti-PD-1 antibody.
    Cancer Lett. 2021;518:49-58.
    PubMed     Abstract available


    September 2021
  27. BHATTARAI PY, Kim G, Poudel M, Lim SC, et al
    METTL3 induces PLX4032 resistance in melanoma by promoting m(6)A-dependent EGFR translation.
    Cancer Lett. 2021;522:44-56.
    PubMed     Abstract available


    July 2021
  28. ZHANG X, Hu Z, Wang X, Li L, et al
    ANXA10 promotes melanoma metastasis by suppressing E3 ligase TRIM41-directed PKD1 degradation.
    Cancer Lett. 2021 Jul 26. pii: S0304-3835(21)00360.
    PubMed     Abstract available


    June 2021
  29. SINGHAL SS, Srivastava S, Mirzapoiazova T, Horne D, et al
    Targeting the mercapturic acid pathway for the treatment of melanoma.
    Cancer Lett. 2021;518:10-22.
    PubMed     Abstract available


    April 2021
  30. COPPO R, Orso F, Virga F, Dalmasso A, et al
    ESDN inhibits melanoma progression by blocking E-selectin expression in endothelial cells via STAT3.
    Cancer Lett. 2021;510:13-23.
    PubMed     Abstract available


    March 2021
  31. GRILLO E, Corsini M, Ravelli C, Zammataro L, et al
    Expression of activated VEGFR2 by R1051Q mutation alters the energy metabolism of Sk-Mel-31 melanoma cells by increasing glutamine dependence.
    Cancer Lett. 2021;507:80-88.
    PubMed     Abstract available


  32. MA Y, Wang L, He F, Yang J, et al
    LACTB suppresses melanoma progression by attenuating PP1A and YAP interaction.
    Cancer Lett. 2021 Mar 3. pii: S0304-3835(21)00101.
    PubMed     Abstract available


    February 2021
  33. LLOPIZ D, Ruiz M, Silva L, Reparaz D, et al
    Inhibition of adjuvant-induced TAM receptors potentiates cancer vaccine immunogenicity and therapeutic efficacy.
    Cancer Lett. 2021;499:279-289.
    PubMed     Abstract available


  34. DANG N, Lin Y, Waer M, Sprangers B, et al
    Immunization with alloantibodies-covered melanoma cells induces regional antitumor effects that become systemic when combined with 5-FU treatment.
    Cancer Lett. 2021;503:151-162.
    PubMed     Abstract available


    January 2021
  35. WU PK, Hong SK, Park JI
    Mortalin depletion induces MEK/ERK-dependent and ANT/CypD-mediated death in vemurafenib-resistant B-Raf(V600E) melanoma cells.
    Cancer Lett. 2021 Jan 10. pii: S0304-3835(21)00007.
    PubMed     Abstract available


  36. GRILLO E, Corsini M, Ravelli C, di Somma M, et al
    A novel variant of VEGFR2 identified by a pan-cancer screening of recurrent somatic mutations in the catalytic domain of tyrosine kinase receptors enhances tumor growth and metastasis.
    Cancer Lett. 2021;496:84-92.
    PubMed     Abstract available


  37. ZHAO Y, Li J, Ting KK, Chen J, et al
    The VE-Cadherin/beta-catenin signalling axis regulates immune cell infiltration into tumours.
    Cancer Lett. 2021;496:1-15.
    PubMed     Abstract available


    December 2020
  38. BOTELHO DE SOUZA LE, Ferreira FU, Thome CH, Brand H, et al
    Human and mouse melanoma cells recapitulate an EMT-like program in response to mesenchymal stromal cells secretome.
    Cancer Lett. 2020 Dec 28. pii: S0304-3835(20)30701.
    PubMed     Abstract available


    November 2020
  39. HARTMAN ML, Gajos-Michniewicz A, Talaj JA, Mielczarek-Lewandowska A, et al
    BH3 mimetics potentiate pro-apoptotic activity of encorafenib in BRAF(V600E) melanoma cells.
    Cancer Lett. 2020 Nov 28. pii: S0304-3835(20)30635.
    PubMed     Abstract available


  40. KIM G, Bhattarai PY, Lim SC, Kim JY, et al
    PIN1 facilitates ubiquitin-mediated degradation of serine/threonine kinase 3 and promotes melanoma development via TAZ activation.
    Cancer Lett. 2020 Nov 27. pii: S0304-3835(20)30631.
    PubMed     Abstract available


    April 2020
  41. TIAN H, Kang Y, Song X, Xu Y, et al
    PDL1-targeted vaccine exhibits potent antitumor activity by simultaneously blocking PD1/PDL1 pathway and activating PDL1-specific immune responses.
    Cancer Lett. 2020;476:170-182.
    PubMed     Abstract available


  42. KUO CL, Chou HY, Chiu YC, Cheng AN, et al
    Mitochondrial oxidative stress by Lon-PYCR1 maintains an immunosuppressive tumor microenvironment that promotes cancer progression and metastasis.
    Cancer Lett. 2020;474:138-150.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.